The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Roles of STAT3 and ZEB1 Proteins in E-cadherin Down-regulation and Human Colorectal Cancer Epithelial-Mesenchymal Transition
Open accessAbstract
The progression of colorectal carcinoma (CRC) to invasive and metastatic disease may involve localized occurrences of epithelial-mesenchymal transition (EMT). However, mechanisms of the EMT process in CRC progression are not fully understood. We previously showed that knockdown of signal transducer and activator of transcription 3 (STAT3) up-regulated E-cadherin (a key component in EMT progression) in CRC. In this study, we examined the roles of STAT3 in CRC EMT and ZEB1, an EMT inducer, in STAT3-induced down-regulation of E-cadherin. Knockdown of STAT3 significantly increased E-cadherin and decreased N-cadherin and vimentin expressions in highly invasive LoVo CRC cells. Meanwhile, overexpression of STAT3 significantly reduced E-cadherin and enhanced N-cadherin and vimentin expressions in weakly invasive SW1116 CRC cells. Activation of STAT3 significantly increased CRC cell invasiveness and resistance to apoptosis. Knockdown of STAT3 dramatically enhanced chemosensitivity of CRC cells to fluorouracil. STAT3 regulated ZEB1 expression in CRC cells, and the STAT3-induced decrease in E-cadherin and cell invasion depended on activation of ZEB1 in CRC cells. Additionally, pSTAT3(Tyr-705) and ZEB1 expressions were significantly correlated with TNM (tumor, lymph node, and metastasis stages) (p < 0.01). In conclusion, STAT3 may directly mediate EMT progression and regulate ZEB1 expression in CRC. ZEB1 may participate in STAT3-induced cell invasion and E-cadherin down-regulation in CRC cells. The expressions of pSTAT3(Tyr-705) and ZEB1 may be positively associated with CRC metastasis. Our data may provide potential targets to prevent and/or treat CRC invasion and metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
The snail superfamily of zinc-finger transcription factors
Nieto, M. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm757 · Cited by 1,719 · cited 1×
“The major transcriptional repressors that are known to down-regulate E-cadherin expression include those in the Snail and ZEB families (6, 47).”
BackgroundEpithelial–mesenchymal transitions in development and pathologies
Thiery, J. P. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.006 · Cited by 1,704
An Overview of Epithelio-Mesenchymal Transformation
Hay, E. D. (1995) · Cells Tissues Organs · doi:10.1159/000147748 · Cited by 1,567
Edelman, G. M. (1983) · Science · doi:10.1126/science.6823544 · Cited by 1,015
Bhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., Arteaga, C. L., & Moses, H. L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.1.27 · Cited by 1,004
Cadherins and cancer: how does cadherin dysfunction promote tumor progression?
Jeanes, A., Gottardi, C. J., & Yap, A. S. (2008) · Oncogene · doi:10.1038/onc.2008.343 · Cited by 772
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
Perez-Moreno, M., Jamora, C., & Fuchs, E. (2003) · Cell · doi:10.1016/s0092-8674(03)00108-9 · Cited by 721
Cited by
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
Self-citationLoh, C.-Y., Chai, J., Tang, T., Wong, W., Sethi, G., Shanmugam, M., Chong, P., & Looi, C. (2019) · Cells · doi:10.3390/cells8101118 · Cited by 1,315
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753
“Likewise, the expression of IL6 negatively correlated with miR-34a (Figure 5I) and positively with mesenchymal markers VIM , ZEB1 , SNAIL , and ZEB2 (Figure 5, J–”
BackgroundInfluentialNon-redundant functions of EMT transcription factors
Stemmler, M. P., Eccles, R. L., Brabletz, S., & Brabletz, T. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0196-y · Cited by 524
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness
Sánchez-Tilló, E., Liu, Y., de Barrios, O., Siles, L., Fanlo, L., Cuatrecasas, M., Darling, D. S., Dean, D. C., Castells, A., & Postigo, A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1122-2 · Cited by 518
STAT3 Target Genes Relevant to Human Cancers
Carpenter, R., & Lo, H.-W. (2014) · Cancers · doi:10.3390/cancers6020897 · Cited by 511
Sun, T.-T., He, J., Liang, Q., Ren, L.-L., Yan, T.-T., Yu, T.-C., Tang, J.-Y., Bao, Y.-J., Hu, Y., Lin, Y., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0921 · Cited by 397
Self-citationLncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
Tang, J., Yan, T., Bao, Y., Shen, C., Yu, C., Zhu, X., Tian, X., Guo, F., Liang, Q., Liu, Q., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11447-8 · Cited by 372
Self-citationTargeting EMT in cancer: opportunities for pharmacological intervention
Davis, F. M., Stewart, T. A., Thompson, E. W., & Monteith, G. R. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.06.006 · Cited by 361
Epithelial–mesenchymal transition in colorectal cancer metastasis: A system review
Cao, H., Xu, E., Liu, H., Wan, L., & Lai, M. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.05.010 · Cited by 356
Loh, C.-Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00048 · Cited by 348
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & De Maria, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 342
Nath, A., Li, I., Roberts, L. R., & Chan, C. (2015) · Scientific Reports · doi:10.1038/srep14752 · Cited by 338
The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer
WANG, S.-W., & SUN, Y.-M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2259 · Cited by 320
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“, 2012), metastasis (Xiong et al., 2012), and cancer stem cell maintenance (Sherry et al.”
BackgroundLIU, R.-Y., ZENG, Y., LEI, Z., WANG, L., YANG, H., LIU, Z., ZHAO, J., & ZHANG, H.-T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2310 · Cited by 308
Pretzsch, E., Bösch, F., Neumann, J., Ganschow, P., Bazhin, A., Guba, M., Werner, J., & Angele, M. (2019) · Journal of Oncology · doi:10.1155/2019/7407190 · Cited by 298
Highlighted STAT3 as a potential drug target for cancer therapy
Lee, H., Jeong, A. J., & Ye, S.-K. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.7.152 · Cited by 295
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer
Hong, J., Guo, F., Lu, S.-Y., Shen, C., Ma, D., Zhang, X., Xie, Y., Yan, T., Yu, T., Sun, T., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-322780 · Cited by 290
Self-citationWang, H., Wang, H.-S., Zhou, B.-H., Li, C.-L., Zhang, F., Wang, X.-F., Zhang, G., Bu, X.-Z., Cai, S.-H., & Du, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056664 · Cited by 273
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Hu, Y., Dong, Z., & Liu, K. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02949-5 · Cited by 268
Li, S.-P., Xu, H.-X., Yu, Y., He, J.-D., Wang, Z., Xu, Y.-J., Wang, C.-Y., Zhang, H.-M., Zhang, R.-X., Zhang, J.-J., et al. (2106) · Oncotarget · doi:10.18632/oncotarget.9883 · Cited by 268
Self-citationZhang, W., Shi, X., Peng, Y., Wu, M., Zhang, P., Xie, R., Wu, Y., Yan, Q., Liu, S., & Wang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129603 · Cited by 261
Self-citationLee, E., Fertig, E. J., Jin, K., Sukumar, S., Pandey, N. B., & Popel, A. S. (2014) · Nature Communications · doi:10.1038/ncomms5715 · Cited by 197
Trinh, A., Trumpi, K., De Sousa E Melo, F., Wang, X., de Jong, J. H., Fessler, E., Kuppen, P. J. K., Reimers, M. S., Swets, M., Koopman, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0680 · Cited by 180
Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
Zhang, T., Li, J., Yin, F., Lin, B., Wang, Z., Xu, J., Wang, H., Zuo, D., Wang, G., Hua, Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.270 · Cited by 132
Self-citationThe multiverse nature of epithelial to mesenchymal transition
Simeone, P., Trerotola, M., Franck, J., Cardon, T., Marchisio, M., Fournier, I., Salzet, M., Maffia, M., & Vergara, D. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.11.004 · Cited by 98
Lewis, K. M., Bharadwaj, U., Eckols, T. K., Kolosov, M., Kasembeli, M. M., Fridley, C., Siller, R., & Tweardy, D. J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.014 · Cited by 63
Wu, X., Lu, R., Wang, L., Wang, Y., Dai, Y., Wang, C., Yang, Y., Guo, F., Xue, J., & Yang, D. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27079 · Cited by 40
Self-citation
Metadata
- Authors
- Xiong, H., Hong, J., Du, W., Lin, Y.-W., Ren, L.-L., Wang, Y.-C., Su, W.-Y., Wang, J.-L., Cui, Y., Wang, Z.-H., & Fang, J.-Y.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 287
- Issue
- 8
- Pages
- 5819-5832
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1996164472
- Cited by
- 307
- References
- 51
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.